Aclaris Therapeutics, Inc. 10-Q filing
Filed 2026-05-07 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001104659-26-057202
- Form type
- 10-Q
- CIK
- 0001557746
- Primary document
- https://www.sec.gov/Archives/edgar/data/1557746/000110465926057202/acrs-20260331x10q.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Aclaris Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $2.0M | - | - |
| Cost Of Revenue | $395,000 | - | - |
| Operating Income | $-22.2M | - | - |
| Net Income | $-19.8M | - | - |
| Eps Basic | -0.15 | - | - |
| Eps Diluted | -0.15 | - | - |
| Cash And Equivalents | $28.7M | - | - |
| Total Assets | $198.7M | - | - |
| Total Liabilities | $55.1M | - | - |
| Shareholders Equity | $143.6M | - | - |
| Operating Cash Flow | $-18.1M | - | - |
| Capital Expenditures | $13,000 | - | - |